News & Events about Allogene Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer,today announced it will present updated data from the Phase 1 ALPHA/ALPHA2...
TipRanks Financial Blog
1month ago
In a report released yesterday, Anthony Butler from EF Hutton maintained a Buy rating on Allogene Therapeutics (ALLO Research Report), with a pri... In a report released yesterday, Anthony Butler from EF Hutton maintained a Buy rating on Allogene Therapeutics (ALLO –...
Data Provide Proof-of-Concept for an Allogeneic Anti-CD70 CAR T Candidate in Patients with Renal Cell Carcinoma (RCC) Who Received Prior Immune Checkpoint Inhibitor and VEGF-Targeting TherapySingle Infusion of ALLO-316 Demonstrates Promising Anti-Tumor Activity in CD70 Expressing RCC Three of 10 ...
Allogene Therapeutics, Inc. (NASDAQ:ALLO Get Rating) hit a new 52-week low during mid-day trading on Monday . The stock traded as low as $4.70 and last traded at $4.68, with a volume of 186273 shares trading hands. The stock had previously closed at $4.89. Analysts Set New Price Targets Several ...
Ticker Report
2 months ago
Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO Get Rating) have been given an average recommendation of Moderate Buy by the thirteen analysts that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell ...